1020719-72-5
Chemical Structure
Penciclovir-d4
Synonym(s): BRL 39123-d4;VSA 671-d4
- CAS No.: 1020719-72-5
- Formula:C10H11D4N5O3
- Molecular Weight:257.28
IUPAC Name: 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl-1,1,2,2-d4)-3,9-dihydro-6H-purin-6-one
InChIKey: JNTOCHDNEULJHD-LNLMKGTHSA-N
SMILES: OCC(CO)C([2H])([2H])C([2H])([2H])N1C2=C(C(N=C(N2)N)=O)N=C1
Biological Activity: Penciclovir-d4 is the deuterium labeled Penciclovir. Penciclovir is reported to be potent against HSV types 1 and 2 with IC50 of 0.04-1.8 μg/mL and 0.06-4.4 μg/mL, respectively[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Penciclovir-d4 | Penciclovir-d4 is the deuterium labeled Penciclovir. Penciclovir is reported to be potent against HSV types 1 and 2 with IC50 of 0.04-1.8 μg/mL and 0.06-4.4 μg/mL, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Penciclovir (Standard) | 99.44% | Penciclovir (Standard) is the analytical standard of Penciclovir. This product is intended for research and analytical applications. Penciclovir (VSA 671) is a potent and selective anti-herpesvirus agent with EC50 values of 0.5, 0.8 µg/ml for HSV-1 (HFEM), HSV-2 (MS), respectively. Penciclovir shows anti-herpesvirus activity with no-toxic. Penciclovir preventes mortality in mouse. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Penciclovir | 99.81% | Penciclovir (VSA 671) is a potent and selective anti-herpesvirus agent with EC50 values of 0.5, 0.8 μg/ml for HSV-1 (HFEM), HSV-2 (MS), respectively. Penciclovir shows anti-herpesvirus activity with no-toxic. Penciclovir preventes mortality in mouse. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Piret J, et al. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011 Feb;55(2):459-72. [Content Brief]